Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus

Qin Zeng; Jianfeng Han; Dong Zhao; Tao Gong; Zhirong Zhang; Xun Sun
January 2012
International Journal of Nanomedicine;2012, Vol. 7, p985
Academic Journal
No abstract available.


Related Articles

  • FX and Host Defense Evasion Tactics by Adenovirus. Baker, Andrew H; Nicklin, Stuart A; Shayakhmetov, Dmitry M // Molecular Therapy;Jun2013, Vol. 21 Issue 6, p1109 

    The article discusses research being done on adenovirus-mediated evasion against host-derived natural antibodies. It references the study "Coagulation Factor X Shields Adenovirus Type 5 From Attack by Natural Antibodies and Complement," by Z. Xu et al. in the 2013 issue of "Nature Medicine." The...

  • Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin. Yang, L.; Wang, L.; Su, X.-q.; Chen, X.-c.; Li, D.; Luo, S.-t.; Shi, H.-s.; Chen, L.-j.; Wang, Y.-s. // Cancer Gene Therapy;Jan2010, Vol. 17 Issue 1, p49 

    Gene therapy using adenoviral vector containing the endostatin gene is a promising strategy for advanced cancers. However, host immune response to adenovirus and the lack of the requisite coxsackie-adenovirus receptor (CAR) in many primary cells limit the in vivo application. Liposome-complexed...

  • Adenovirus-based Prime-boost Immunization for Rapid Vaccination Against Anthrax. McConnell, Michael J.; Hanna, Philip C.; Imperiale, Michael J. // Molecular Therapy;Jan2007, Vol. 15 Issue 1, p203 

    Prime-boost vaccination using plasmid DNA and replication-defective adenovirus vectors has emerged as a highly effective strategy for vaccinating against viral pathogens. However, its ability to provide protection against bacterial disease has never been assessed. Here we evaluate prime-boost...

  • Genetic Vaccine for Respiratory Syncytial Virus Provides Protection Without Disease Potentiation. Johnson, Teresa R; Rangel, David; Graham, Barney S; Brough, Douglas E; Gall, Jason G // Molecular Therapy;Jan2014, Vol. 22 Issue 1, p196 

    Respiratory syncytial virus (RSV) is a major cause of infectious lower respiratory disease in infants and the elderly. As there is no vaccine for RSV, we developed a genetic vaccine approach that induced protection of the entire respiratory tract from a single parenteral administration. The...

  • Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses. Bruder, Joseph T.; Semenova, Elena; Ping Chen; Limbach, Keith; Patterson, Noelle B.; Stefaniak, Maureen E.; Konovalova, Svetlana; Thomas, Charlie; Hamilton, Melissa; King, Richter; Richie, Thomas L.; Doolan, Denise L. // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    The development of an effective malaria vaccine is a high global health priority. Vaccine vectors based on adenovirus type 5 are capable of generating robust and protective T cell and antibody responses in animal models and are currently being evaluated in clinical trials for HIV and malaria....

  • Effective repeat administration with adenovirus vectors to the muscle. Chen, P; Kovesdi, I; Bruder, J T // Gene Therapy;Apr2000, Vol. 7 Issue 7, p587 

    Effective repeat administration of adenovirus vectors following intranasal or intravenous delivery is hindered by a strong neutralizing antibody response to the vector. Intramuscular administration of adenovirus vectors elicited a neutralizing antibody response that peaked between 14 and 21 days...

  • Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. Antrobus, Richard D; Coughlan, Lynda; Berthoud, Tamara K; Dicks, Matthew D; Hill, Adrian VS; Lambe, Teresa; Gilbert, Sarah C // Molecular Therapy;Mar2014, Vol. 22 Issue 3, p668 

    Adenoviruses are potent vectors for inducing and boosting cellular immunity to encoded recombinant antigens. However, the widespread seroprevalence of neutralizing antibodies to common human adenovirus serotypes limits their use. Simian adenoviruses do not suffer from the same drawbacks. We have...

  • Adenoviral vectors: Adenoviral vectors, breaking a barrier to gene therapy? Blair, G. Eric // Gene Therapy;Feb2004, Vol. 11 Issue 3, p229 

    Focuses on a targeted approach to transient suppression of the immune system in a primate model of adenovirus gene therapy, using chimeric human monoclonal antibodies against two key molecules involve in the stimulation of the immune response, namely CD40 and CD80. Decrease in neutralizing...

  • Chimpanzee-origin adenovirus vectors as vaccine carriers. Tatsis, N.; Tesema, L.; Robinson, E. R.; Giles-Davis, W.; McCoy, K.; Gao, G. P.; Wilson, J. M.; Ertl, H. C. J. // Gene Therapy;Mar2006, Vol. 13 Issue 5, p421 

    Vaccines based on replication-defective adenoviral vectors are being developed for infectious agents and tumor-associated antigens. Early work focused on vaccines derived from a common human serotype of adenovirus, that is, adenovirus of the serotype 5 (AdHu5). Neutralizing antibodies against...

  • Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. Frahm, Nicole; DeCamp, Allan C.; Friedrich, David P.; Carter, Donald K.; Defawe, Olivier D.; Kublin, James G.; Casimiro, Danilo R.; Duerr, Ann; Robertson, Michael N.; Buchbinder, Susan P.; Yunda Huang; Spies, Gregory A.; De Rosa, Stephen C.; McElrath, M. Juliana // Journal of Clinical Investigation;Jan2012, Vol. 122 Issue 1, p359 

    Recombinant viruses hold promise as vectors for vaccines to prevent infectious diseases with significant global health impacts. One of their major limitations is that preexisting anti-vector neutralizing antibodies can reduce T cell responses to the insert antigens; however, the impact of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics